Last Updated : June 29, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Vesicare | Solifenacin succinate | Bladder, overactive | Do not list | Complete | ||
Vesicare | Solifenacin succinate | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
VesiFlow | Solifenacin succinate / tamsulosin hydrochloride | Benign prostatic hyperplasia | Withdrawn | |||
VFEND | Voriconazole | Aspergillosis, Invasive | Withdrawn | |||
VFEND | Voriconazole | Aspergillosis, Invasive | List with clinical criteria and/or conditions | Complete | ||
VFEND | Voriconazole | Candidemia | List with clinical criteria and/or conditions | Complete | ||
Viacoram | perindopril arginine / amlodipine | Hypertension, essential | Reimburse with clinical criteria and/or conditions | Complete | ||
Viberzi | eluxadoline | Irritable bowel syndrome with diarrhea | Do not reimburse | Complete | ||
Victoza | liraglutide | Diabetes Mellitus, Type 2 (pediatric) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Victoza | Liraglutide | Diabetes Mellitus, Type 2 | Withdrawn | |||
Victoza | Liraglutide | Diabetes mellitus, Type 2 | Do not list | Complete | ||
Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Victrelis | Boceprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
Viibryd | vilazodone | Depression, Major depressive disorder | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Reimburse with clinical criteria and/or conditions | Complete | ||
Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Do not list | Complete | ||
Vimpat | Lacosamide | Epilepsy, partial onset seizures | List with clinical criteria and/or conditions | Complete | ||
Viread | Tenofovir disoproxil fumarate | HIV infection | Do not list | Complete | ||
Viread | Tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Viread | Tenofovir disoproxil fumarate | HIV infection | N/A | Complete | ||
Viread | Tenofovir disoproxil fumarate | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete | ||
Visanne | Dienogest | Pain, pelvic pain associated with endometriosis | List with clinical criteria and/or conditions | Complete | ||
Vitrakvi | larotrectinib | Solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete | ||
Vitrakvi | Larotrectinib | NTRKplus solid tumours | Do not reimburse | Complete |